1Fukuoka M,Yano S,Giacone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.J Clin Oncol,2003,21:2237-2246. 被引量：1
2Stewart LA,Pignon JP.Non-Small Cell Collaborative Group.Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomized clinical trials.Br Med J,1995,311:899-907. 被引量：1
3Muggia FM.The cancer therapy evaluation program of the national cancer institute.Semi Oncol,1981,8:349. 被引量：1
3Fukuoka M,Yano S,Ciacone G,et al.Mulfi-institutionai randomized phase Ⅱtrial of gefitinib for previously treated patients With advanced non-small-cell lung cancer[J].J Clin Onenl,2003,21(12):2237-2246. 被引量：1
4Stamatis G,Eberhard W,P6ttgen C,el al.Surgery after muitimodality treatment for non-small-cell lung cancer[J].Lung Cancer,2004,45(Suppl 2):S 107-S112. 被引量：1
5Machtay M,Lee JH,Stevenson JP,el al.TWO commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage Ⅲ non-small cell lung carcinoma:long-term results and associations with pathologic response[J].J Thorac Cardiovasc Surg,2004,127(1):108-113. 被引量：1
6Pearson FG, Cooper JD, Deslauriers J, et al. Thoracic surgery [ M]. 2nd ed. Philadelphia: Churchill Livingstone,2002. 被引量：1
7Fukuoka M, Yano S, Giacone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer ( The IDEAL 1 Trial) [ J]. J Clin Oncol, 2003,21 (12) :2237 -2246. 被引量：1
8Marttn M, Ruiz A, Munoz M, et al. Gemcitabine plus viuorelbiue versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final re- suits of the phase III Spanish Breast Cancer Research Group (GEI- CAM) trial [ J]. Lancet Oncol,2007,8 (3) :219 - 225. 被引量：1
9Osako T, Horii R, Ogiya A, et al. Histogenesis of metaplastic breast carcinoma and axillary nodal metastases [ J ]. Pathol Int, 2009,59 (2) :116 -120. 被引量：1
10Matsumoto S, Batra S, Saito K, et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hy- poxia [ J ]. Cancer Res ,2011,71 (20) :6350 - 6359. 被引量：1
